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Background: Sphingosine-1-phosphate receptor-2, S1P2, is expressed in vascular 
endothelial cells (EC). However, the role of S1P2 in vascular barrier integrity and 
anaphylaxis is not well understood. Endothelial nitric oxide (NO) synthase (eNOS) 
generates NO to mediate vascular leakage, compromising survival in anaphylaxis. We 
recently observed that endothelial S1P2 inhibits Akt, an activating kinase of eNOS.  
Objective: We tested the hypothesis that endothelial S1P2 might suppress eNOS, 
exerting a protective effect against endothelial barrier-disruption and anaphylaxis. 
Methods: Mice deficient in S1P2 and eNOS underwent antigen challenge or 
platelet-activating factor (PAF) injection. Analyses were performed to examine 
vascular permeability and the underlying mechanisms. 
Results: S1pr2 deletion augmented vascular leakage and lethality after either antigen 
challenge or PAF injection. PAF injection induced activation of Akt and eNOS in the 
aorta and lung of S1pr2-null mice, which were augmented compared with wild-type 
mice. Consistently, PAF-induced increase in cyclic GMP level in the aorta was 
enhanced in S1pr-null mice. Genetic Nos3 deletion or pharmacological eNOS 
blockade protected S1pr2-null mice from aggravation of barrier-disruption after 
antigen challenge and PAF injection. EC isolated from S1pr2-null mice exhibited 
greater stimulation of Akt and eNOS with enhanced NO production in response to 
S1P or PAF, compared with wild-type EC. Moreover, S1pr2-deficient EC showed 
more severe disassembly of adherens junctions with augmented S-nitrosylation of 
β-catenin in response to PAF, which was restored by pharmacological eNOS 
blockade.  
Conclusion: S1P2 diminishes harmful robust eNOS stimulation and thereby attenuates 
vascular barrier-disruption, suggesting potential usefulness of S1P2 agonists as novel 
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therapeutic agents for anaphylaxis. 
 
Key Messages 
•Endothelial S1P2 plays a protective role against acute barrier disruption during 
anaphylaxis. 
•The barrier-protective effect of S1P2 is mediated through suppression of eNOS. 
 
Capsule Summary 
Endothelial S1P2 protects against vascular leakage in anaphylaxis through suppressing 
production of nitric oxide, which disrupts the endothelial barrier, and could be a 
promising novel target for treating anaphylaxis. 
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AJ: adherens junctions 
BSA: bovine serum albumin 
cGMP: cyclic GMP  
EC: endothelial cell 
eNOS: endothelial NO synthase 
HCT: hematocrit 
L-NAME: Nω-L-nitro-argininemethyl ester 
MLEC: mouse lung endothelial cell  
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NO: nitric oxide 
OVA: ovalbumin 
PAF: platelet-activating factor  
PI3K: phosphatidylinositol 3-kinase 
PTEN: phosphatase and tensin homolog deleted from chromosome 10 
S1P: sphingosine-1-phosphate 






















Sphingosine-1-phosphate (S1P) has been identified as an important regulator of 
vascular and immune functions.1, 2 S1P is synthesized by sphingosine kinases-1 and -2 
in a wide variety of cells.3 Plasma S1P, which is present at the concentration of ~10-6 
M, is derived from erythrocytes, vascular endothelial cells (EC) and other cells.4-6 
Most of the biological activities of S1P are mediated by the S1P-specific G 
protein-coupled receptor family S1P1~ S1P5.
7 Among these, S1P1, S1P2 and S1P3 are 
widely expressed major receptor subtypes. EC in culture express readily detectable 
levels of S1P1 and S1P3 whereas S1P2 expression is much lower or undetectable.
8, 9 
However, we recently observed by analyzing LacZ-knockin mice at the S1pr2 locus 
that EC in a variety of organs express S1P2 in vivo.
10 S1P1 and S1P2 exert distinct 
effects on cell responses, including migration and proliferation, through the 
preferential coupling to Gi and G12/13, respectively.
11 
Platelet-activating factor (PAF), histamine and leukotrienes are edematogenic 
mediators that disrupt vascular barrier integrity, which is sustained mainly by the 
endothelial adherens junction (AJ) comprising VE-cadherin and its associated 
proteins.12 In anaphylaxis, these edematogenic mediators are released mainly from 
mast cells through antigen engagement of mast cell-associated IgE and act on vascular 
endothelium and smooth muscle to cause severe vascular leakage and hypotension.13 
To establish novel therapies for anaphylaxis, it is important to better understand the 
pathophysiological mechanisms underlying vascular barrier disruption. Both in vitro 
and in vivo studies have documented that S1P maintains vascular endothelial barrier 
function via endothelial S1P1.
14,15 A subsequent study showed that plasma S1P is 
required to prevent vascular leakage in anaphylaxis after antigen challenge or 
injections of PAF and histamine.16 Thus, the plasma S1P–endothelial S1P1 axis plays 
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a central role in maintaining vascular barrier integrity.17 In contrast to S1P1, 
pharmacological blockade of S1P2 was reported to reduce histamine-induced vascular 
leakage.18 More recently, it has been shown that genetic deletion of S1pr2 attenuated 
vascular leakage and hypothermia in anaphylaxis after antigen challenge.19 S1pr2  
deletion was accompanied by diminished elevation of plasma histamine and cytokines 
after antigen challenge, suggesting that stimulation of mast cell activation by S1P2 is a 
determinant of vascular hyperpermeability and anaphylaxis. Unlike this report, 
however, another group showed that S1P2 was rather vital for recovery from 
histamine-induced hypothermia through regulating vascular tone and histamine 
clearance, which suggests that S1P2 exerts a protective effect against anaphylaxis at a 
site distal to mast cell activation.20, 21 Thus, the in vivo role of S1P2 in anaphylaxis is 
not yet fully understood. 
Previous studies demonstrated that endothelial nitric oxide (NO) synthase (eNOS 
or NOS3)-derived NO is involved in an increase of vascular permeability caused by 
PAF and vascular endothelial growth factor-A (VEGF).22-24 The activity of the 
calmodulin-dependent enzyme eNOS is stimulated by an increase in intracellular free 
Ca2+, interaction with regulatory proteins, and phosphorylation mediated largely by 
Ca2+-independent protein kinases including Akt and protein kinase A.25 
Phosphorylation of eNOS sensitizes eNOS to Ca2+, resulting in augmented activation 
of eNOS. Most edematogenic mediators, including PAF and histamine, act through G 
protein-coupled receptors. Importantly, anaphylactic shock has been shown to depend 
on eNOS activation mediated by endothelial Gq/11 and phosphatidylinositol 3-kinase 
(PI3K)-Akt.26,27 We recently found that endogenous S1P2 mediates inhibition of Akt 
in EC,10 unlike S1P1 which stimulates eNOS via Akt.
28 These observations raise the 
possibility that S1P2 might suppress eNOS through inhibition of Akt, exerting a 
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rescue effect on vascular hyperpermeability.  
In the present study, we tested this hypothesis by determining how genetic Nos3  
deletion and pharmacological eNOS blockade affected S1P2-mediated effects on 
vascular hyperpermeability in anaphylaxis in mice. Our results indicate that S1P2 
protects mice from vascular barrier disruption elicited by either antigen challenge or 
PAF injection and that this protective effect of S1P2 is mediated through suppression 
of anaphylaxis-associated eNOS stimulation. These observations provide the basis for 

























All animal experiments were conducted according to the Fundamental Guidelines 
for Proper Conduct of Animal Experiment and Related Activities in Academic 
Research Institutions under the jurisdiction of the Ministry of Education, Culture, 
Sports, Science and Technology of Japan, and were approved by the Committee on 
Animal Experimentation of Kanazawa University. S1pr2-null (S1pr2-/-) mice were 
previously described.10 S1pr2-/- mice (129Ola;C57BL/6J mixed background) were 
back-crossed with C57BL/6J mice (#000664, Charles River) once. In some 
experiments, we employed another S1pr2–deleted (S1pr2LacZ/LacZ) mouse in which 
LacZ is knocked in at the S1pr2 locus.10 Nos3-/- mice (#002684, C57BL/6J 
background) were obtained from the Jackson Laboratory. S1pr2-/-; Nos3-/- mice and 
wild-type (WT) littermates were generated by heterozygous matings.  
 
Statistics  
All values are expressed as mean ± SEM. Data were analyzed using unpaired, 
two-tailed Student’s t-test, and two-way ANOVA followed by Bonferroni post test to 
determine statistical significance using GraphPad Prism software. Values of P< 0.05 







S1P2 protects mice from vascular hyperpermeability in anaphylaxis 
We studied how S1P2 affected vascular hyperpermeability and mortality using two 
models of active systemic anaphylaxis, which predominantly depends on PAF.29 Mice 
had been sensitized with bovine serum albumin (BSA) or ovalbumin (OVA) and 
challenged with these antigens. After BSA challenge, S1pr2-/- mice displayed greater 
extravasation of i.v. injected Evans blue in the lung compared with WT mice (Fig 1, A 
and B). Consistent with this, S1pr2-/- mice showed higher hematocrit (HCT) due to 
augmented plasma leakage compared with WT mice (Fig 1, C). Evans blue leakage 
under saline administration was similar in S1pr2-/- and WT mice, suggesting that basal 
vascular permeability was not altered in S1pr2-/- mice. S1pr2-/- mice began to die 
within 10 min after the antigen challenge and all S1pr2-/- mice died by 30 min, 
whereas WT mice started to die as late as 25 min and 45% of WT mice survived the 
antigen challenge at 60 min (Fig 1, D). Similarly, in OVA-sensitized S1pr2-/- mice, 
challenge with OVA augmented Evans blue leakage and HCT elevation compared 
with those in WT mice (Fig E1). 
   We next studied the vascular permeability responses to i.v. injection of the 
anaphylactic mediator PAF. S1pr2-/- mice showed greater PAF-induced extravasation 
of Evans blue dye in the lung than did WT mice (Fig E2, A and B). Histological 
analysis of the lungs showed more pronounced accumulation of perivascular fluid in 
S1pr2-/-mice after PAF injection, compared with WT mice (Fig E2, C). S1pr2-/- mice 
exhibited higher HCT compared with that of WT mice at 10 min after PAF injection 
(Fig E2, D). Consequently, survival after PAF injection was severely impaired in 
S1pr2-/- mice: 90% of WT mice survived PAF challenge whereas less than 10% of 
S1pr2-/- mice survived (Fig E2, E). We also analyzed the effect of PAF on dermal 
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vascular permeability in S1pr2-/- and WT mice using a Miles assay. Basal vascular 
permeability was similar in S1pr2-/- and WT mice (Fig E2, F). Intradermal injection of 
PAF induced a dose-dependent increase in leakage of Evans blue dye in both 
genotypes, with greater leakage of Evans blue in S1pr2-/- mice compared with WT 
mice. S1pr2-/- mice also displayed enhanced dermal leakage of Evans blue dye after 
local histamine injection compared with WT mice (data not shown). To delineate how 
the genetic background of mice affected the anaphylactic responses, we analyzed 
S1pr2LacZ/LacZ mice10 that had been back-crossed with C57BL/6 mice 4 times and WT 
littermates. S1pr2LacZ/LacZ mice showed exaggerated responses of Evans blue leakage 
and HCT elevation after PAF challenge compared with WT mice (Fig E3), which 
were similar to those in S1pr2-/- mice. In these experiments, we anesthetized mice for 
a very short time (~1 min) with ether. In the non-anesthetized condition, we observed 
essentially the same exaggerated responses in HCT and death after PAF injection in 
S1pr2-/- mice compared with WT mice (Fig E4). These data indicate that S1pr2-/- mice 
show enhanced vascular permeability with increased mortality in anaphylaxis.  
 
Akt/eNOS activation is augmented in aorta and lung of S1pr2-/- mice after PAF 
challenge 
S1pr2-/- and WT mice, which received saline injection, showed similar levels of basal 
phosphorylation of Akt (Fig 2, A and C) and eNOS (Fig 2, B and D) in both aorta and 
lung. PAF injection stimulated Akt phosphorylation in aorta from both S1pr2-/-and WT 
mice but with a greater increase in S1pr2-/- mice (Fig 2, A). In contrast, PAF-induced 
activation of ERK or p38MAPK was not different between S1pr2-/-and WT mice (data 
not shown). Notably, PAF injection increased eNOS phosphorylation in aorta from 
both mouse groups with a greater degree of stimulation in S1pr2-/- mice (Fig 2, B). 
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Similarly to aorta, PAF increased phosphorylation in Akt and eNOS in lung from both 
S1pr2-/- and WT mice with greater degrees of stimulation in S1pr2-/- mice (Fig 2, C 
and D). NO synthesized by eNOS stimulates the formation of cyclic GMP (cGMP) in 
vascular wall. The basal level of cGMP in aorta was similar between S1pr2-/- and WT 
mice (Fig 2, E). PAF injection induced a larger increase in aortic cGMP level in 
S1pr2-/- mice than in WT mice. These observations raise the possibility that the 
exaggerated increase in vascular permeability in S1pr2-/- mice might be due to 
augmented activation of the Akt/eNOS signaling pathway and generation of NO in the 
vasculature. 
 
Pharmacological inhibition of NO synthase or genetic deletion of Nos3 protect 
S1pr2-/- mice from vascular hyperpermeability in anaphylaxis 
Administration of Nω-L-nitro-argininemethyl ester (L-NAME) 3 h before PAF 
injection prevented the exaggerated HCT elevation after PAF challenge in S1pr2-/- 
mice (Fig E5, A). L-NAME also protected S1pr2-/- mice against PAF-induced lethality 
(Fig E5, B). These observations suggest that NO is involved in PAF-induced vascular 
leakage and lethality in S1pr2-/-mice. To elucidate the role of eNOS in exaggerated 
PAF-induced vascular leakage in S1pr2-/-mice, we crossed S1pr2-/- mice with Nos3-/- 
mice to generate S1pr2-/-;Nos3-/- compound mutant mice. The HCT after PAF injection 
in S1pr2-/-;Nos3-/- mice was lower than that in S1pr2-/- mice and was not different from 
that in WT mice or Nos3-/- mice (Fig 3, A). Thus, augmentation of the PAF-induced 
HCT elevation in S1pr2-/-mice was abolished by Nos3 deficiency. Consistently, 
S1pr2-/-;Nos3-/- mice were almost completely rescued from PAF-induced lethality (Fig 
3, B).  
We also studied the effects of Nos3 deficiency on vascular responses in 
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anaphylaxis after BSA challenge. The magnitude of the increase in plasma histamine 
level after antigen challenge was similar in WT, S1pr2-/-, Nos3-/-, and S1pr2-/-;Nos3-/- 
mice (Fig E6, A). The HCT at 10 min after antigen challenge in S1pr2-/-;Nos3-/- mice 
was lower than that in S1pr2-/- mice and similar to that in WT mice and Nos3-/- mice 
(Fig 3, C). These observations suggest that eNOS in the vascular endothelium is 
responsible for S1pr2 deficiency-induced aggravation of vascular hyperpermeability 
in anaphylaxis. We studied the hypotensive response to an antigen challenge in these 
mutant mice. A previous study30 documented that in S1pr2-/- mice, the in vivo pressor 
response and the in vitro vascular contractile response to phenylephrine were 
diminished, the latter of which was endothelium-dependent. S1pr2-/- mice showed 
significantly lower steady state systolic and diastolic blood pressure than WT mice 
while both Nos3-/- mice and S1pr2-/-;Nos3-/- mice displayed higher systolic blood 
pressure than WT mice (Table E1). Antigen challenge induced a rapid drop in blood 
pressure to a level of ∼40 mmHg in anesthetized WT mice, and hypotension persisted 
for more than 40 min (Fig 3, D). In S1pr2-/- mice, blood pressure declined more 
rapidly and became unmeasurably low, leading to death within 25 min. Under the 
same condition, S1pr2-/-;Nos3-/- mice and Nos3-/- mice showed only a mild, transient 
reduction in blood pressure and recovered by 50 min. These observations indicate that 
S1pr2-/- mice exhibit severe fatal circulatory shock and that deletion of Nos3 gene 
protects both S1pr2-/- and WT mice from anaphylactic shock. Antigen challenge in 
WT mice induced a decline in core body temperature (mean change of -1.6°C at 20 
min) (Fig E6, B). S1pr2-/- mice displayed more severe hypothermia compared with 
WT mice. S1pr2-/-;Nos3-/- mice and Nos3-/- mice exhibited only a mild, transient 
decrease in body temperature, which was less marked compared with that in WT mice. 
Consistent with all these data, S1pr2-/-;Nos3-/- mice were protected from antigen 
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challenge-induced lethality: S1pr2-/- single mutant mice started to die at 8 min after 
antigen challenge with 85% mortality at 60 min, whereas S1pr2-/-;Nos3-/- mice began 
to die at 45 min and mortality at 60 min was 38% (Fig 3, E). Nos3-/- single mutant 
mice were also protected from antigen challenge-induced lethality as reported 
previously.26 
 
S1P2 negatively regulates Akt–eNOS pathway in vascular EC  
In lung EC (MLEC) from WT mice, PAF stimulated phosphorylation of both Akt and 
eNOS (Fig 4, A and B). S1P alone did not affect phosphorylation of Akt or eNOS but 
rather reduced PAF-induced phosphorylation of eNOS in WT MLEC. In contrast to 
WT MLEC, S1P by itself stimulated phosphorylation of Akt and eNOS in S1pr2-/- 
MLEC. This is most likely because S1P1, which is a major S1P receptor in S1pr2-/- 
MLEC, mediated S1P-induced phosphorylation of Akt and eNOS whereas S1P2 
counteracted S1P1-mediated phosphorylation of Akt and eNOS in WT MLEC.  
Furthermore, PAF stimulated phosphorylation of Akt and eNOS to a greater degree in 
S1pr2-/- MLEC compared with WT MLEC. Unlike WT MLEC, S1P did not reduce 
PAF-induced phosphorylation of Akt and eNOS in S1pr2-/- MLEC, so that 
phosphorylation of Akt and eNOS in S1pr2-/- MLEC stimulated with S1P plus PAF 
was substantially greater than in WT MLEC. We examined how S1P2 affected the 
production of NO in MLEC. In MLEC isolated from WT mice, either PAF or VEGF 
but not S1P stimulated the generation of NO (Fig 4, C). In S1pr2-/- MLEC, PAF and 
VEGF stimulated NO production to a greater degree compared with WT EC. 
Moreover, S1P by itself modestly stimulated NO production in S1pr2-/- MLEC, which 
was consistent with the results of eNOS phosphorylation (Fig 4, B). In addition, S1P 
slightly enhanced PAF-induced NO production in S1pr2-/- MLEC. These observations 
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suggest that S1P2 exerts inhibitory effects on NO production in EC through reducing 
phosphorylation of Akt and eNOS. 
 
S1P2 contributes to maintaining AJ through inhibiting PAF-induced 
S-nitrosylation of β-catenin 
NO mediates disruption of endothelial AJ, which comprise VE-cadherin and 
intracellular associated proteins including β-catenin and p120 catenin,12 and increases 
vascular permeability.22, 23, 25 Recent studies31, 34 demonstrated that VEGF stimulation 
of eNOS induced S-nitrosylation of β-catenin, leading to disassembly of AJ 
complexes. We examined how S1P2 influenced PAF-induced disassembly of AJ and 
S-nitrosylation of β-catenin in a monolayer of MLEC. Immunofluorescent staining 
with anti-VE-cadherin and anti-β-catenin antibodies showed that VE-cadherin and 
β-catenin were uniformly distributed at cell-cell contacts in both WT and S1pr2-/- 
MLEC in a non-treated condition, indicating that AJ were formed (Fig 5, A). PAF 
treatment resulted in a discontinuous, zigzag pattern of staining of both VE-cadherin 
and β-catenin in both WT and S1pr2-/- MLEC, indicating disruption of AJ. 
PAF-induced disruption of AJ was more severe in S1pr2-/- MLEC than in WT MLEC. 
Pretreatment with L-NAME almost totally prevented disruption of AJ in both WT and 
S1pr2-/- MLEC. We analyzed S-nitrosylation of β-catenin in MLEC treated with PAF 
and S1P in the presence and absence of L-NAME. In WT EC, PAF plus S1P tended to 
increase S-nitrosylation of β-catenin but not significantly (Fig 5, B). In contrast, PAF 
plus S1P substantially increased S-nitrosylation of β-catenin in S1pr2-/- MLEC. 
L-NAME abolished S-nitrosylation of β-catenin induced by PAF plus S1P in both WT 
and S1pr2-/- MLEC. These results suggest that S1P2 inhibits PAF-induced disassembly 
of AJ through mechanisms involving inhibition of NO production and thereby 
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The present study provides evidence supporting that S1P2 is protective against acute 
vascular barrier disruption, based on the composite results obtained in two 
anaphylaxis models of antigen challenge and PAF injection. Our study also revealed 
the mechanisms underlying the protective effect of S1P2: S1P2 suppressed harmful 
robust activation of eNOS, which plays a key role in vascular leakage in anaphylaxis. 
Thus, our study identified the role of a novel endothelial signaling pathway 
comprising S1P2–Akt inhibition–eNOS inhibition, which plays a protective role 
against vascular barrier-disruption and may represent a promising new target for 
treating vascular hyperpermeability.  
We studied the effects of S1pr2 deficiency on acute vascular barrier disruption in 
active anaphylaxis and PAF injection. In the active anaphylaxis model, our data 
demonstrated that S1pr2 deficiency exacerbated vascular leakage, hypotension, 
hypothermia and lethality without causing an increase in plasma histamine level (Figs 
1 and 3, and Fig E6). Moreover, S1pr2 exacerbated vascular leakage and lethality 
provoked by injection of the anaphylactic mediator PAF (Fig E2). These results 
together imply that S1P2 alleviates acute vascular permeability largely by acting at a 
site distal to the release of anaphylactic mediators from mast cells; i.e., very likely at 
the vasculature itself. Our observations are consistent with the studies by Olivera et 
al.,20, 21 which showed that histamine injection-induced hypothermia and hypotension 
were aggravated in S1pr2-/- mice, but are not consistent with that by Oskeritzian et 
al.,19 which showed that S1pr2 deficiency alleviated vascular leakage and 
hypothermia after antigen challenge, contrasting to our study. The findings by 
Oskeritzian et al.19 also differ from our observations, in that PAF or histamine 
injection-induced vascular leakage and hypothermia were not different between 
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S1pr2-/- and WT mice. The reasons for the discrepancies between their study and the 
present study are not clear. However, it is possible that a difference in the 
experimental models, i.e., passive anaphylaxis19 vs. active anaphylaxis (our study), 
might have led to the different results. The genetic backgrounds of mice were not 
exactly identical but very similar (mixed background of C57BL/6 x 129/Sv19 vs. 
back-crossing once or twice of C57BL/6 x 129/Ola with C57BL/6 (our study)).  
The present study demonstrated that endothelial S1P2 inhibits eNOS (Fig 4). 
S1pr2 deficiency de-inhibits eNOS in the vasculature in vivo (Fig 2). NO generated 
by eNOS is involved in vascular hyperpermeability in response to pro-inflammatory 
mediators such as PAF and VEGF.22-24 Moreover, acute hypotension and lethality after 
antigen challenge and PAF injection entirely depend on the PI3K/Akt/eNOS 
pathway.26 Our results also showed that inhibition of eNOS action by genetic or 
pharmacological manipulation in S1pr2-/- mice markedly improved vascular leakage, 
hypotension and survival rate after antigen challenge, thus abrogating the effects of 
S1pr2 deficiency (Fig 3 and Fig E5). All these observations together indicate that 
S1P2 provides a protective effect against vascular barrier disruption largely by 
suppressing eNOS.  
NO regulates many biological processes including vasorelaxation, through 
stimulating soluble guanylate cyclase and cGMP production.32 However, the previous 
study26 showed that a specific inhibitor of soluble guanylate cyclase or genetic 
deletion of soluble guanylate cyclase-α1, a major isoform in the vasculature, did not 
protect mice from PAF-induced lethality, suggesting that NO might mediate shock in 
a manner independent of cGMP. In addition to guanylate cyclase–cGMP, NO may 
affect biological processes through causing S-nitrosylation of proteins.33 AJ control 
endothelial barrier function.12 Recent studies showed that VEGF induced 
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S-nitrosylation of β-catenin, resulting in the dissociation of β-catenin from 
VE-cadherin and disassembly of AJ complexes.31, 34 In pulmonary EC, PAF and S1P 
induced S-nitrosylation of β-catenin with disassembly of VE-cadherin and β-catenin 
at cell-cell contacts, which was augmented by S1pr2 deficiency (Fig 5). Of note, 
pharmacological blockade of eNOS restored the aggravation of S-nitrosylation of 
β-catenin and AJ disassembly by S1pr2 deficiency. Therefore, our data together with 
these recent observations indicate that S1P2 exerts a protective effect on barrier 
functions through mechanisms involving inhibition of S-nitrosylation of β-catenin and 
consequent disassembly of the AJ.  
Akt is a major Ca2+-independent eNOS-activating protein kinase.35 S1pr2 
deficiency augmented activation of Akt as well as eNOS in the vasculature (Fig 2). 
Therefore, it is likely that increased Akt activity at least in part mediates enhanced 
eNOS phosphorylation in S1pr2-/- mice. Endogenously expressed S1P2 is nearly 
exclusively coupled to G12/13 and downstream Rho.
36 S1P2 was previously shown to 
stimulate 3’-specific phosphatase of phosphoinositides, “phosphatase and tensin 
homolog deleted from chromosome 10 (PTEN)”, via Rho kinase.37 
Phosphatidylinositol-3,4,5-P3 generated by PI3K mediates Akt stimulation. 
S1P2-mediated stimulation of PTEN decreases the cellular level of 
phosphatidylinositol-3,4,5-P3, thereby resulting in inhibition of Akt activation.
37 The 
previous gene knockout study by Korhonen et al.27 showed that endothelial 
Gq/11-mediated signaling is crucially involved in NO formation and vascular barrier 
disruption induced by PAF and other mediators. Gq/11 mediates activation of the 
calmodulin-dependent enzyme eNOS through both mechanisms of Ca2+ mobilization 
and Akt-mediated eNOS phosphorylation.35 Hence, the study by Korhonen et al.27 and 
our study together suggest that the PAF receptor, which is a Gq/11–coupled receptor, 
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mediates an increase in vascular permeability through eNOS stimulation whereas 
S1P2 counteracts this Gq/11-mediated action through G12/13-mediated suppression of 
the Akt–eNOS pathway. 
Among the S1P receptors, S1P1 has been shown to potentiate endothelial barrier 
integrity in vivo and in vitro.8, 14, 38 A recent study using sphingosine kinases-null mice 
indicated that plasma S1P is required for vascular integrity.16 Furthermore, 
administration of synthetic S1P1 agonists, which powerfully induce downregulation of 
S1P1, but also that of S1P1 antagonists induced pulmonary edema.
15, 17, 39 Therefore, 
S1P1 seems to maintain vascular integrity in a tonic manner.
16 S1P1 and S1P2 activate 
distinct signaling pathways: S1P1 mediates Gi-dependent Rac activation, which is 
implicated in the vascular barrier integrity-maintaining action of S1P1,
8, 14 whereas 
S1P2 mediates inhibition of Rac via G12/13.
10, 36 Moreover, S1P1 stimulates eNOS 
phosphorylation through Gi–PI3K–Akt, unlike S1P2.
40 However, the stimulatory 
effect of S1P1 on phosphorylation of Akt and eNOS seems to be counteracted by S1P2 
in WT EC, as suggested by our observation that S1P increased phosphorylation of Akt 
and eNOS in S1pr2-deficient EC but not WT EC (Fig 4). These distinct signaling 
properties likely underlie the differential roles of S1P1 and S1P2 in the regulation of 
barrier integrity: S1pr2 deficiency does not affect baseline vascular permeability but 
prevents enhanced vascular leakage after antigen challenge or injections of PAF and 
histamine (Figs 1, and Figs E1 and E2).20 Consistent with this is the previous 
observation that baseline permeability was not affected by the presence or absence of 
eNOS.22, 23 Different from S1P2, S1P1 maintains not only constitutive barrier integrity 
but protects against barrier disruption caused by anaphylaxis and inflammation.15, 16, 39 
It is likely that S1P1 protects the integrity of AJ through a mechanism different from 
eNOS–NO regulation. Thus, these observations together with the previous 
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observations27 suggest that receptor signaling mediated by Gq/11, Gi and G12/13 play 
distinct critical roles in triggering, preventing and limiting vascular leakage. 
We have demonstrated that S1P2 suppresses stimulation of eNOS and NO 
generation in EC through inhibition of Akt during anaphylaxis. As a result, S1P2 
protects against the disassembly of endothelial AJ by inhibiting S-nitrosylation of 
β-catenin, and thereby vascular leakage. An S1P2-selective agonist may have a 
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Figure 1. S1pr2 deficiency exacerbates vascular leakage in active anaphylaxis. Mice 
that had been sensitized with BSA were challenged with i.v. injection of BSA. (A and 
B) Evans blue leakage in lungs of mice 10 min after BSA challenge or saline infusion. 
(A) Representative lung photographs. (B) Quantification of Evans blue leakage in 
lung. (C) HCT 10 min after BSA challenge. (D) Survival of BSA-challenged WT and 
S1pr2-/- mice. Numbers in parentheses denote numbers of mice or samples analyzed 
throughout the Figures. The following symbols are used throughout the Figures. * p< 
0.05; ** p < 0.01; *** p < 0.001. If not marked, differences were not statistically 
significant.  
 
Figure 2. S1pr2 deficiency augments PAF injection-induced phosphorylation of Akt 
and eNOS in aorta and lung and production of cGMP in aorta. (A-D) PAF-stimulated 
phosphorylation of Akt at Ser473 and eNOS at Ser1177 in aorta (A and B) and lung (C 
and D) of WT and S1pr2-/- mice that were i.v. injected with saline or PAF. (E) PAF 
injection-stimulated increase in cGMP level in aorta. Cyclic GMP was extracted and 
determined using an ELISA kit.  
 
Figure 3. Genetic eNOS deficiency restores aggravation of vascular leakage after 
PAF injection and antigen challenge in S1pr2 deficient mice. (A) HCT 10 min after 
PAF injection in WT and S1pr2-/- mice with or without Nos3 deficiency. (B) Survival 
after PAF injection of WT and S1pr2-/- mice with or without Nos3 deficiency. (C) 
HCT 10 min after BSA challenge in S1pr2+/+ and S1pr2-/- mice with or without Nos3 
deficiency. (D) Changes in mean arterial blood pressure after BSA challenge in 
S1pr2+/+ and S1pr2-/- mice with or without Nos3 deficiency. (E) Survival after BSA 
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challenge of S1pr2+/+ and S1pr2-/- mice with or without Nos3 deficiency. 
 
Figure 4. PAF- and S1P-stimulated phosphorylation of Akt and eNOS and production 
of NO are exaggerated in S1pr2 deficient EC. (A and B) PAF (100 nM)- and S1P (100 
nM)-stimulated phosphorylation of Akt at Ser473 (A) and eNOS at Ser1177 (B) in lung 
endothelial cells (MLEC) isolated from WT and S1pr2-/- mice. Serum-starved MLEC 
were stimulated as indicated for 20 min. Top: representative blots. Bottom: quantified 
data. (C) PAF (50 nM)-, VEGF-A165 (10 ng/ml)- and S1P (100 nM)-stimulated 





Figure 5. PAF-induced disruption of AJ is aggravated by S1pr2 deficiency and 
rescued by a NOS inhibitor in EC. (A) Immunofluorescent staining using 
anti-VE-cadherin (green) or anti-β-catenin antibody (red) in MLEC. MLEC were 
stimulated or not with PAF (100 nM) for 30 min with or without L-NAME (1 mM) in 
the presence of 1% fetal bovine serum. Bars, 20 µm. (B) PAF- and S1P-induced 
S-nitrosylation of β-catenin in MLEC. Serum-starved MLEC were pretreated or not 
with S1P (30 nM) plus L-NAME (1 mM) or S1P alone for 10 min and then stimulated 
with PAF (100 nM) for 30 min, followed by analysis using the biotin-switch method 
and western blotting with anti-β-catenin antibody. Left: representative blots. Right: 
quantified data of S-nitroso-β-catenin.  











